The selective serotonin reuptake inhibitor (SSRI) paroxetine provides benefits for patients with fibromyalgia, according to a study presented at the 157th Annual Meeting of the American Psychiatric Association [New York, US; May 2004]. In this placebo-controlled study, treatment with controlled-release paroxetine was well tolerated and produced improvements from baseline in fibromyalgia symptoms in a significantly greater proportion of patients, compared with placebo.